Clinical Trial

Study of YOLT-202 in the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Name: Study of YOLT-202 in the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) — clinical trial record (NCT07193615)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: AATD

Active, Not Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

This is a single-arm, open-label, single-dose, dose-escalation exploratory study to evaluate the safety and tolerability of a single dose of YOLT-202 in patients with AATD and determine the optimal biologically active dose (OBD) of YOLT-202.

Trial Details

NCT Number	NCT07193615
Lead Sponsor	RenJi Hospital
Conditions	Alpha-1 Antitrypsin Deficiency (AATD)
Enrollment	18 participants
Start Date	2025-06-18
Primary Completion	2027-01 (estimated)
Study Completion	2027-03 (estimated)
Updated on ClinicalTrials.gov	2025-09-26